Surrozen (SRZN) FDA Approvals $29.32 -0.68 (-2.27%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$29.54 +0.22 (+0.73%) As of 10/2/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest Surrozen's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Surrozen (SRZN). Over the past two years, Surrozen has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as SZN-8141. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. SZN-8141 FDA Regulatory Events SZN-8141 is a drug developed by Surrozen for the following indication: for the Treatment of Diabetic Macular Edema. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - October 2,2026Provided Update INDDrug: SZN-8141Announced Date: October 2, 2026Indication: for the Treatment of Diabetic Macular EdemaAnnouncementSurrozen, Inc announced its Investigational New Drug (IND) application for SZN-8141 has become effective, enabling the Company to advance the program into clinical development. SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor (VEGF) antagonist antibody being developed as an intravitreal injection for the treatment of diabetic macular edema (DME).Read Announcement Surrozen FDA Events - Frequently Asked Questions Has Surrozen received FDA approval? As of now, Surrozen (SRZN) has not received any FDA approvals for its therapy in the last two years. What drugs has Surrozen submitted to the FDA? In the past two years, Surrozen (SRZN) has reported FDA regulatory activity for SZN-8141. What is the most recent FDA event for Surrozen? The most recent FDA-related event for Surrozen occurred on October 2, 2026, involving SZN-8141. The update was categorized as "Provided Update," with the company reporting: "Surrozen, Inc announced its Investigational New Drug (IND) application for SZN-8141 has become effective, enabling the Company to advance the program into clinical development. SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor (VEGF) antagonist antibody being developed as an intravitreal injection for the treatment of diabetic macular edema (DME)." What conditions do Surrozen's current drugs treat? Currently, Surrozen has one therapy (SZN-8141) targeting the following condition: for the Treatment of Diabetic Macular Edema. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Agenus FDA EventsInflaRx FDA EventsCentury Therapeutics FDA EventsObsidian Therapeutics FDA EventsSurrozen FDA EventsVera Therapeutics FDA EventsVerastem FDA EventsJohnson & Johnson FDA EventsTeva Pharmaceutical Industries FDA EventsAktis Oncology FDA EventsAgomAb Therapeutics FDA EventsArtiva Biotherapeutics FDA EventsArvinas FDA EventsBioCardia FDA EventsCandel Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Kailera Therapeutics FDA Events Nanobiotix FDA Events Omeros FDA Events Oric Pharmaceuticals FDA Events Damora Therapeutics, Inc. Common Stock FDA Events Replimune Group FDA Events MannKind FDA Events Bicara Therapeutics FDA Events Vor Biopharma FDA Events Immatics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:SRZN last updated on 10/2/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredFree Stock: Economist calls it “the world’s most important machine.”Nvidia's most expensive chip component isn't made by Nvidia. Jeff Brown, former semiconductor executive, says ...Brownstone Research | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surrozen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - October 2,2026Provided Update INDDrug: SZN-8141Announced Date: October 2, 2026Indication: for the Treatment of Diabetic Macular EdemaAnnouncementSurrozen, Inc announced its Investigational New Drug (IND) application for SZN-8141 has become effective, enabling the Company to advance the program into clinical development. SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor (VEGF) antagonist antibody being developed as an intravitreal injection for the treatment of diabetic macular edema (DME).Read Announcement
